HB3851, titled the SBIR/STTR Pilot Extension Act, would amend the Small Business Act to extend several existing Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) pilot authorities through September 30, 2030. The bill focuses on programs that help small businesses move federally funded research toward commercialization, including the direct-to-Phase II authority, the commercialization readiness program for civilian agencies, the Phase 0 proof-of-concept partnership program, and commercialization assistance pilot programs.
In addition to extending these programs, the bill broadens the direct-to-Phase II authority by allowing any federal agency that runs an SBIR program to use it, rather than limiting it to the National Institutes of Health, the Department of Defense, and the Department of Education. It also adds new limits on how much of an agency’s SBIR funds may be awarded under that authority in a fiscal year: generally up to 10 percent, with a higher 15 percent cap for NIH. Agencies using the authority would also have to report the number and amount of awards in their next required SBIR report.
Impact
The bill would amend section 9 of the Small Business Act, 15 U.S.C. 638, by extending expiration dates for multiple SBIR/STTR pilot programs and revising the scope and reporting requirements for direct-to-Phase II awards. Its practical effect would be to preserve and expand federal pathways for small businesses to receive research and commercialization funding, while imposing agency-level award caps and additional transparency requirements. The legislation would affect federal agencies that administer SBIR programs, especially NIH and other civilian and defense agencies that may use these pilot authorities.
Sentiment
Based on the bill text and available context, the measure appears to be a routine reauthorization and expansion of established innovation programs, with no recorded committee debate or votes indicating opposition or controversy. The overall sentiment is likely favorable or at least pragmatic, since the bill extends programs that support small business research, commercialization, and technology transfer. The absence of transcripts or vote history suggests the bill had not yet generated notable public disagreement in the available record.
Contention
The main policy issue embedded in the bill is the expansion of direct-to-Phase II authority to all SBIR agencies, which could raise questions about program consistency, oversight, and whether agencies should have broad discretion to bypass earlier-stage awards. The new 10 percent cap, and NIH’s higher 15 percent cap, may also be points of interest for agencies and stakeholders concerned about how much of the SBIR budget can be concentrated in this award type. However, no specific objections, supporters, or negotiated compromises are reflected in the available committee materials.